While the Pharma-Bio Industry is classified as an essential industry in the era of COVID-19, it is becoming apparent that a number of big-ticket projects are being shut down. California and Pennsylvania were the first two states to issue stay-in-place orders, and it soon became clear that non-essential large capex projects had ground to a halt.

In California, Bayer shut down its $150 million cell culture tech center in Berkeley, as did Cytokinetics and its $200 million project in South San Francisco.